Ananda Developments Plc to Conduct Phase IIIa Trials for Cannabis-Based Medicines in Treating Drug-Resistant Epilepsy

Strategic Insights -

Ananda Developments Plc has announced that its cannabis-based medicines, MRX2 (CBD) and MRX2T (CBD+THC), will be used in two major NHS-backed phase IIIa trials exploring treatments for drug-resistant epilepsy. The trials aim to test whether the medicines can reduce seizures and improve participants' quality of life in patients with drug-resistant epilepsy. Researchers at University College London and Great Ormond Street Hospital will lead the research, which will involve 500 children and adults from across the UK.

Key Takeaways:

  • The trials will test the efficacy and safety of Ananda's MRX2 and MRX2T medicines in reducing seizures and improving quality of life in patients with drug-resistant epilepsy.
  • The research will examine not only seizure control but also other factors such as learning, sleep, behaviour, and overall quality of life.
  • The trials are expected to last 24 weeks, with patients receiving either one of Ananda's treatments or a placebo.
  • The research is co-funded by the NHS and National Institute for Health and Care Research, with the goal of gaining approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) and other regulatory bodies.
  • Ananda will supply the medicines for the trials and hopes to expand its role in the development of cannabinoid-based epilepsy treatments.
  • The UK government spends around £2 billion annually on epilepsy treatment, with much of this cost focused on patients with treatment-resistant epilepsy.

Statistics:

  • The trials will involve 500 children and adults from across the UK.
  • The research will last 24 weeks.
  • Ananda's MRX2 and MRX2T medicines will be tested against a placebo in patients with drug-resistant epilepsy.
  • The trials are co-funded by the NHS and National Institute for Health and Care Research.

Sources:

  • Source: Ananda Developments Plc press release (no date)
  • Source: "NHS-backed trials to explore treatment of drug-resistant epilepsy" (no publication date)